详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

TMB is associated with the prognosis of egfr-mutated non-small cell lung cancer in Xuanwei, China

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE

作者：

机构： [1]First Peoples Hosp Yunnan Prov, Dept Thorac Surg, Kunming, Yunnan, Peoples R China [2]Yunnan Univ Tradit Chinese Med, Sch Nursing, Kunming, Yunnan, Peoples R China [3]Zhaotong Hlth Vocat Coll, Key Lab Northeastern Yunnan Nat Med, Zhaotong, Yunnan, Peoples R China [4]Kunming Univ Sci & Technol, Anning Peoples Hosp 1, Kunming, Yunnan, Peoples R China [5]3D Med Inc, Med Dept, Shanghai, Peoples R China

出处：

DOI：

ISSN：

关键词： NSCLC Xuanwei EGFR TMB Prognosis

摘要：

Aims: Study on the prognostic characteristics and biomarkers of lung cancer in Xuanwei Patients. Materials and Methods: A retrospective analysis was conducted on the genetic data of 261 NSCLC patients, as well as the prognostic data of 133 patients. The relationship between prognosis and EGFR mutations in the Xuanwei and non Xuanwei cohorts was compared and analyzed. Results: The superior progression-free survival (PFS) in Xuanwei patients was primarily observed in those with EGFR-mutated tumors (p < 0.05). Further analysis of accompanying mutations and TMB levels revealed an association between high TMB and a favorable prognosis in EGFR-mutated Xuanwei NSCLC. Conclusion: Xuanwei lung cancer differs from non Xuanwei patients in terms of prognosis and tumor mutation burden, and further research should be conducted.

基金：

语种：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学：研究与实验

JCR分区：

出版当年[2023]版：

Q3 MEDICINE, RESEARCH & EXPERIMENTAL

最新[2023]版：

Q3 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 1.9 最新[2023版] 2.2 最新五年平均 1.9 出版当年[2023版] 2.2 出版当年五年平均 2.2 出版前一年[2022版]

第一作者：

第一作者机构： [1]First Peoples Hosp Yunnan Prov, Dept Thorac Surg, Kunming, Yunnan, Peoples R China

共同第一作者：

通讯作者：

通讯机构： [1]First Peoples Hosp Yunnan Prov, Dept Thorac Surg, Kunming, Yunnan, Peoples R China [3]Zhaotong Hlth Vocat Coll, Key Lab Northeastern Yunnan Nat Med, Zhaotong, Yunnan, Peoples R China [4]Kunming Univ Sci & Technol, Anning Peoples Hosp 1, Kunming, Yunnan, Peoples R China [5]3D Med Inc, Med Dept, Shanghai, Peoples R China [*1]603 Yucai Rd, Zhaotong 657000, Yunnan, Peoples R China [*2]157 Jin Bi Rd, Kunming 650031, Yunnan, Peoples R China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]The clinical implications of TMB and the relationship between TMB and EGFR mutations in non-small cell lung cancer of Xuanwei, China [2]Next-Generation Sequencing Reveals High Uncommon EGFR Mutations and Tumour Mutation Burden in a Subgroup of Lung Cancer Patients [3]Mutational Profile of Multiple Lung Cancers in Xuanwei by Next-Generation Sequencing [4]Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study [5]Various Subtypes of EGFR Mutations in Patients With NSCLC Define Genetic, Immunologic Diversity and Possess Different Prognostic Biomarkers [6]Plasma MiRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations [7]Efficacy and safety of befotertinib (D-0316) in patients with EGFR T790M mutated non-small cell lung cancer that had progressed after prior EGFR TKI therapy: A phase 2, multicenter, single-arm, open-label study. [8]Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area [9]Rh-endostatin Combined With PD-1 inhibitors as Firstline Treatment for EGFR/ALK-Negative, Nonsquamous NSCLC [10]Decreased expression of NEDD4L contributes to NSCLC progression and metastasis